Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7207
Reference
Name
COVID-19 therapeutic alert: interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pnuemonia (adults)
Categories
Scottish Government
Drug Alerts
Organization
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
Description
Attaches a letter about the findings of the REMAP-CAP trial about the recovery benefits for tocilizumab or sarilumab, over and above standard care for ICU patients with COVID-19 pneumonia.
Contact Name
Contact Email
Contact Address
Contact Phone
Created
2021-01-08 00:00:00
Click to go back to homepage